The government on Friday said that two vaccines Covishield and Covaxin have been seen working against SARS-CoV-2 variants Alpha, Beta, Gamma, and Delta, while the tests for the effectiveness of the vaccines against the Delta variant is still going on. The variants of concern that are creating a global concern at present are Alpha, Beta, Gamma, and Delta, while the Delta Plus variant is being a sub-lineage of the Delta variant which is also a variant of concern.
ICMR Director General Balram Bhargava while addressing a press conference, said the reduction of neutralisation capabilities of vaccine with different variants, which is based on global literature, shows that Covaxin does not change with the Alpha variant at all and so it is the same as it is with the standard strain.
“Covishield reduces slightly with Alpha, by 2.5 times. For the Delta variant, Covaxin is effective but antibody response is slightly reduced to three-fold reduction, and for Covishield, it is a two-fold reduction, while in Pfizer and Moderna it is a seven-fold reduction,” he said. “However, Covishield and Covaxin work against the variants of SARS-CoV-2- Alpha, Beta, Gamma, and Delta — that is well established for these two vaccines,” Bhargava said.
While talking about the Delta Plus variant Bhargava said that it is present in 12 countries currently. In India, there are 48 cases in 10 states but they are very localised, added the Indian Council of Medical Research (ICMR) chief.
“The Delta Plus variant has also been isolated and cultured at ICMR-NIV, and laboratory tests to check vaccine effect on Delta Plus variant are ongoing. We should have these results in seven-10 days as to whether the vaccine is working against the Delta Plus variant,” he said.
He said that there are 15-17 mutations in the Delta variants and was first reported in October last year, which was responsible for more than 60 percent of cases in Maharashtra in February.
Bhargava further said that it has already spread to 80 countries. The B.1.617 strain has three subtypes B.1.617.1, B.1.617.2 and B.1.617.3 — and B.1.617.2 (Delta variant) and has been classified as a variant of concern and it has increased transmissibility, potential reduction, stronger binding to receptors of lung cells in monoclonal antibody response and potential post-vaccination immune system.
The B.1.617.2 Plus or Delta Plus variant, detected in different parts of India, characterisation of which are ongoing (three mutations), Bhargava said. In total there about 16 countries where more than 25 per cent of cases of Delta variant have been found, he informed. These countries include Australia, Bahrain, Bangladesh, India, Indonesia, Israel, Japan, Kenya, Myanmar, Peru, Portugal, Russia, Singapore, South Korea, United Kingdom, United States of America.
The second wave of COVID-19 is not yet over, said Bhargava. “We have still got 75 districts which have more than 10 per cent prevalence. We have 92 districts which have between five-10 per cent prevalence and 565 districts are less than five per cent prevalence so in large part of India second wave is over, he said. However, these districts are important and it is possible to avert the third wave provided individuals and society adhere to protective behaviours,” Bhargava said.
“We must avoid mass gathering, use masks correctly and consistently, and any indicative hotspots we find they need to be immediately identified that is what we have done with Delta Plus variant, and isolated people and vaccination has been initiated for these people and district level test positivity rate is posted on the health ministry website, he said.
Data needs to clearly monitored by districts to ensure if the rate is going beyond five per cent, the ICMR chief said. Then we need to impose strict restrictions and that is the most important point that will guide us through the pandemic,” he added.
Bhargava said public health prevention strategies do not change with variants. “Covid appropriate behaviour and vaccination has to continue but continuous monitoring of mutations is important to track vaccine escape, increased transmissibility and disease severity. The next step is, if need be, vaccine composition can be changed as per the circulating variants of interest and variants of concern that can also be done with RNA vaccines and adenovirus-based vaccine can also be modified,” he said.
